NVCR icon

NovoCure

17.46 USD
+0.45
2.65%
At close Updated May 20, 12:40 PM EDT
1 day
2.65%
5 days
-3.7%
1 month
37.81%
3 months
53.7%
6 months
52.36%
Year to date
33.08%
1 year
-4.07%
5 years
-90.42%
10 years
50.52%
 

About: NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Employees: 1,605

0
Funds holding %
of 8,007 funds
0
Analysts bullish %
of 1 analysts
0
Positive news %
of 6 articles
Price charts implemented using Lightweight Charts™